The vaccine primes neoantigen-specific T cells that kill tumor cells presenting those neoantigen peptides (primarily via HLA class I) through perforin/granzyme-mediated lysis; HLA-DQB1 is only an antigen-presenting molecule, not the cytotoxic target.